Additionally, regulatory hurdles, such as the Complete Response Letter (CRL) received for the Eylea HD pre-filled syringe, have created obstacles for the company’s near-term growth plans.

Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Additionally, regulatory hurdles, such as the Complete Response Letter (CRL) received for the Eylea HD pre-filled syringe, have created obstacles for the company’s near-term growth plans. However, ...

Biotech company Regeneron (NASDAQ:REGN) in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP ...

Regeneron's first-quarter results miss on lower Eylea demand Regeneron's first-quarter ... 2025 US FDA approves syringe version of Argenx's immune disorder drug The U.S. Food and Drug ...

Selarsdi is available in various formats, including prefilled syringes, vials for subcutaneous injection ... of Yesafili (aflibercept-jbvf), an interchangeable biosimilar to Eylea (aflibercept).

A case analysis provides a new understanding of the ocular side effects of Blenrep, an antibody drug conjugate that is being ...